title: Dapsone for thrombocytopenic purpura related to human immunodeficiency virus infection.
abstract: OBJECTIVE
  The purpose of this study was to determine the effect of dapsone on platelet count in patients with human immunodeficiency virus (HIV)-related autoimmune thrombocytopenia.
  
  
  METHODS
  Eleven patients with HIV-related thrombocytopenia received dapsone (50 to 125 mg/day) for 2 to 43 months. Patients with the acquired immunodeficiency syndrome were not enrolled.
  
  
  RESULTS
  Of the 11 patients, six developed platelet counts above 50 X 10(9)/L and did not require any other specific therapy. No significant side effects were observed.
  
  
  CONCLUSIONS
  We conclude that dapsone may be effective in some patients with HIV-related thrombocytopenia.
authors.affiliation: Clinique Médicale B, Pr M. Mongin, CHU Timone, Marseille, France.
authors.forename: J M
authors.initials: JM
authors.lastname: Durand
authors.forename: P
authors.initials: P
authors.lastname: Lefèvre
authors.forename: P
authors.initials: P
authors.lastname: Hovette
authors.forename: S
authors.initials: S
authors.lastname: Issifi
authors.forename: M
authors.initials: M
authors.lastname: Mongin
mesh_terms: D000328:Adult; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000209:etiology; D003622:Dapsone / Q000627:therapeutic use*; D005260:Female; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D010976:Platelet Count / Q000187:drug effects; D011696:Purpura, Thrombocytopenic / Q000188:drug therapy* / Q000209:etiology
chemical_list: D003622:Dapsone